HomeAI · summaries
Storia in 4 fonti
Alnylam defends heart disease drugs after failure of AstraZeneca’s Wainua
An AstraZeneca heart disease trial failure has put Alnylam under pressure. It's mounting a defense of its medicines.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease
Results published in NEJM raised questions about the benefits “silencer” medications provide on top of standard therapies for TTR cardiomyopathy and amplified investor pressure on…
- ·
endpoints.news
Future of AstraZeneca’s gene silencer in heart disease uncertain after trial failure
AstraZeneca and Ionis's Wainua misses in Phase 3 heart trial CARDIO-TTRansform, likely due to overlap with Pfizer's Vyndamax; AZ weighs next steps.
